Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217–22.

Article  PubMed  PubMed Central  Google Scholar 

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

Article  PubMed  Google Scholar 

Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–803.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017;123(21):4106–13.

Article  PubMed  Google Scholar 

Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.

Article  CAS  PubMed  Google Scholar 

Chao YK, Chan SC, Liu YH, et al. Pretreatment T3–4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Ann Surg. 2009;249(3):392–6.

Article  PubMed  Google Scholar 

Park JW, Kim JH, Choi EK, et al. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;81(3):691–7.

Article  PubMed  Google Scholar 

Wu Y-Y, Dai L, Yang Y-B, et al. Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-023-14809-1.

Article  PubMed  PubMed Central  Google Scholar 

Yun JK, Kim Y, Lee GD, et al. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. Cancer Med. 2022;11(19):3623–32.

Article  PubMed  PubMed Central  Google Scholar 

Okamura A, Watanabe M, Okui J, et al. Outcomes of patients with esophageal squamous cell carcinoma who achieved a pathological complete response in the primary lesion by neoadjuvant treatment: a Japanese nationwide cohort study. Esophagus. 2024;21(1):2–10.

Article  PubMed  Google Scholar 

Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery. J Thorac Cardiovasc Surg. 2019;157(3):1249-1259.e1245.

Article  PubMed  Google Scholar 

La Mendola R, Bencivenga M, Torroni L, et al. Pretreatment primary tumor stage is a risk factor for recurrence in patients with esophageal squamous cell carcinoma who achieve pathological complete response after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2021;28(6):3034–43.

Article  PubMed  Google Scholar 

Luc G, Gronnier C, Lebreton G, et al. Predictive factors of recurrence in patients with pathological complete response after esophagectomy following neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter study. Ann Surg Oncol. 2015;22(Suppl 3):S1357-1364.

Article  PubMed  Google Scholar 

Kim MK, Cho KJ, Park SI, et al. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):115–21.

Article  PubMed  Google Scholar 

Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23(2):646–54.

Article  PubMed  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(7):855–83.

Article  CAS  PubMed  Google Scholar 

Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36–42.

Article  PubMed  Google Scholar 

Yun JK, Lee IS, Gong CS, et al. Clinical utility of robot-assisted transthoracic esophagectomy in advanced esophageal cancer after neoadjuvant chemoradiation therapy. J Thorac Dis. 2019;11(7):2913–23.

Article  PubMed  PubMed Central  Google Scholar 

Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comp Stat Data Anal. 2003;43(2):121–37.

Article  Google Scholar 

Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.

Article  PubMed  PubMed Central  Google Scholar 

Cheng YF, Chen HS, Wu SC, et al. Esophageal squamous cell carcinoma and prognosis in Taiwan. Cancer Med. 2018;7(9):4193–201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oshikiri T, Goto H, Kato T, et al. Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy: unification of the AJCC staging system and the Japanese classification. Eur J Surg Oncol. 2022;8(8):1760–7.

Article  Google Scholar 

Wong IYH, Chung JCY, Zhang RQ, et al. A novel tumor staging system incorporating tumor regression grade (TRG) with lymph node status (ypN-Category) results in better prognostication than ypTNM stage groups after neoadjuvant therapy for esophageal squamous cell carcinoma. Ann Surg. 2022;276(5):784–91.

Article  PubMed  Google Scholar 

Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2016;29(1):79–85.

Article  CAS  PubMed  Google Scholar 

Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12.

Article  CAS  PubMed  Google Scholar 

He Y-F, Luo H-Q, Wang W, et al. Preoperative NLR and PLR in the middle or lower ESCC patients with radical operation. Eur J Cancer Care (Engl). 2017;26(2):e12445.

Article  Google Scholar 

Wu Y, Chen J, Zhao L, et al. Prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma incorporating hematological biomarkers. Cancer Res Treat. 2021;53(1):172–83.

Article  CAS  PubMed  Google Scholar 

Hyder J, Boggs DH, Hanna A, Suntharalingam M, Chuong MD. Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients. J Gastrointest Oncol. 2016;7(2):189–95.

PubMed  PubMed Central  Google Scholar 

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

Article  CAS  PubMed  Google Scholar 

Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12(2):107–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–49.

Article  CAS  PubMed  Google Scholar 

Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173.

Article